Back to Results

A Phase II, randomized, double-blind, study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

Study category: Cancer

Is this Study for You?

Let's Get Started!

Description

This is a phase II, randomized, double-blind, trial for the use of Rucaparib as maintenance therapy in metastatic and recurrent endometrial cancer.

Details
Age

Adult

Eligibility

Females aged 18-89 with primary stage III/IV or recurrent endometrial cancer whom have received at least one prior chemotherapy regimen and no more than two prior cytoxic regimens (including hormonal therapy).

Type of Study

Treatment

Locations

Fox Chase Cancer Center
University of Colorado Hospital
University of Pennsylvania
University of Pittsburgh Cancer Institute

Principal Investigator
Bradley Corr,  MD

Bradley Corr, MD

Study ID

Protocol Number: 18-0567

More information available at ClinicalTrials.gov: NCT03617679

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers